Panakeia develops AI-driven molecular profiling that extracts multi-omics and biomarker information directly from routine H&E-stained tissue images. Our software-only PANProfiler platform delivers clinically actionable results in minutes, removing the need for wet-lab workflows, reducing costs and turnaround times for cancer diagnostics and accelerating drug development.

We partner with hospitals, pathology labs and biopharma to provide instrument-free precision diagnostics and scalable biomarker discovery. Panakeia’s solutions support faster patient stratification, improve clinical decision-making, and enable reproducible molecular insights at scale. The company has completed multi-site validations and achieved regulatory approvals (UKCA) for key products.